---
title: "Remote ambulation monitoring improves composite disability endpoints in MS and reduces trial sampl"
id: "medrxiv-5-remote-ambulation-monitoring-enhances-composite-disability-measurement-in-ms-to"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-5-remote-ambulation-monitoring-enhances-composite-disability-measurement-in-ms-to"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.03.26361524v1?rss=1"
published_at: "2026-09-07T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Remote ambulation monitoring improves composite disability endpoints in MS and reduces trial sampl
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-5-remote-ambulation-monitoring-enhances-composite-disability-measurement-in-ms-to
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.03.26361524v1?rss=1)
- **Published At:** 2026-09-07T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study presents a framework that converts high-frequency, smartphone-based gait assessments into progression events to complement clinic-based measures in multiple sclerosis (MS). - A new **digitally enhanced composite endpoint** blends remote digital progression events with traditional clinical progression events, aiming to capture disability changes more frequently and sensitively. - The framework was evaluated using data from the Phase 3b CONSONANCE study (N = 667). The digitally enhanced endpoint was directly compared with the original **composite confirmed disability progression (cCDP)** endpoint. - At Week 48, the digitally enhanced endpoint reduced the required **trial sample size** by 24.9% compared with the original cCDP endpoint, indicating improved efficiency for event-based trials. - The digitally enhanced composite also reached equivalent **statistical power** 24 weeks earlier in the study timeline (Week 72 vs Week 96), suggesting the potential to shorten observation periods by 25%. - Authors propose this framework as a practical pathway to optimize clinical trial efficiency in MS and potentially other neurological disorders where ambulatory function is relevant. - The work uses remote smartphone gait monitoring to increase the frequency of outcome measurement, addressing limitations of infrequent in-clinic testing for event-based endpoints. - Data-sharing details: Roche’s Global Policy on Sharing of Clinical Study Information applies; requests require a detailed hypothesis-driven statistical analysis plan and should be directed to dbm.datarequest@roche.com. Linking anonymized records across external sources is discouraged due to reidentification risk. - Ethical oversight: approvals were obtained from the Black Country Research Ethics Committee of the UK Health Research Authority and Health and Care Research Wales for the ISRCTN15993728 study; equivalent local Institutional Review Boards and Ethics Committees approved the decentralized NCT03523858 trial and a full list is in the Supplementary Material. - Competing interests are disclosed: authors include Roche employees, consultants, contractors, and investigators with various industry relationships; funding declared from Roche (Switzerland).
## Clinical Analysis & Structured Key Points
Remote ambulation monitoring enhances composite disability measurement in MS to deliver reduced trial sample size | medRxiv Skip to main content Remote ambulation monitoring enhances composite disability measurement in MS to deliver reduced trial sample size View ORCID Profile Andrea Festanti , View ORCID Profile Dimitar Stanev , View ORCID Profile Cedric Simillion , View ORCID Profile João Rodrigues , View ORCID Profile Letizia Leocani , View ORCID Profile Agne Kazlauskaite , View ORCID Profile James Overell , View ORCID Profile Johannes Lorscheider , View ORCID Profile Gary Cutter , View ORCID Profile Helmut Butzkueven , View ORCID Profile Licinio Craveiro , View ORCID Profile Mike D Rinderknecht doi: https://doi.org/10.64898/2026.09.03.26361524 Andrea Festanti 1 F. Hoffmann-La Roche Ltd., Basel, Switzerland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Andrea Festanti Dimitar Stanev 1 F. Hoffmann-La Roche Ltd., Basel, Switzerland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Dimitar Stanev Cedric Simillion 1 F. Hoffmann-La Roche Ltd., Basel, Switzerland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Cedric Simillion João Rodrigues 1 F. Hoffmann-La Roche Ltd., Basel, Switzerland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for João Rodrigues Letizia Leocani 2 Faculty of Medicine, University Vita-Salute San Raffaele, Milan, Italy; Scientific Institute IRCCS San Raffaele, Milan, Italy; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Letizia Leocani Agne Kazlauskaite 1 F. Hoffmann-La Roche Ltd., Basel, Switzerland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Agne Kazlauskaite James Overell 1 F. Hoffmann-La Roche Ltd., Basel, Switzerland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for James Overell Johannes Lorscheider 3 Reha Rheinfelden, Rheinfelden, Switzerland; Department of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Johannes Lorscheider Gary Cutter 4 Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Gary Cutter Helmut Butzkueven 5 Department of Neuroscience, School for Translational Medicine, Monash University, Melbourne, Australia; Department of Neurology, Alfred Health, Melbourne, Australia Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Helmut Butzkueven Licinio Craveiro 1 F. Hoffmann-La Roche Ltd., Basel, Switzerland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Licinio Craveiro Mike D Rinderknecht 1 F. Hoffmann-La Roche Ltd., Basel, Switzerland; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Mike D Rinderknecht For correspondence: mike.rinderknecht{at}external.roche.com Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract In multiple sclerosis trials, event-based endpoints like the composite confirmed disability progression (cCDP) are often limited by infrequent in-clinic testing. We present a framework that converts high-frequency, remote smartphone-based gait assessments into progression events, and establishes a new composite endpoint that blends digital and clinical progression events. Evaluated in the Phase 3b CONSONANCE study (N = 667), this digitally enhanced endpoint reduced required trial sample size by 24.9% at Week 48 compared to the original cCDP. Furthermore, it achieved equivalent statistical power 24 weeks earlier (Week 72 vs Week 96), demonstrating potential to shorten trial observation periods by 25%. In conclusion, this framework provides a practical pathway to optimize clinical trial efficiency in MS and other neurological conditions, potentially reshaping the path to therapeutic innovation. Competing Interest Statement AF is a contractor for F. Hoffmann-La Roche Ltd. DS is a consultant for F. Hoffmann-La Roche Ltd. CS is an employee of F. Hoffmann-La Roche Ltd JR is a consultant for F. Hoffmann-La Roche Ltd. LL has received compensation for consulting services from Almirall, EXCEMED, F. Hoffmann-La Roche Ltd, Merck, Novartis, Biogen, Janssen-Cilag and Bristol Myers Squibb. AK is an employee of and shareholder in F. Hoffmann-La Roche Ltd. JO is an employee of and shareholder in F. Hoffmann-La Roche Ltd. JL's former institution (University Hospital Basel) has received grants from Innosuisse - Swiss Innovation Agency, the MSBase Foundation, Novartis, and Biogen and honoraria for advisory boards and/or speaking fees from Novartis, Roche and Teva exclusively used for funding research. He received travel compensation from Novartis and Bristol Myers Squibb. GC has received compensation for participation in data and safety monitoring boards for Applied Therapeutics, AI Therapeutics, AMO Pharma, Argenx, AstraZeneca, Avexis Pharmaceuticals, Bristol Meyers Squibb, CSL Behring, Cynata Therapeutics, DiaMedica Therapeutics, Horizon Pharmaceuticals, Immunic, Inhibrix, Karuna Therapeutics, Kezar Life Sciences, Medtronic, Merck, Meiji Seika Pharma, Mitsubishi Tanabe Pharma Holdings, Prothena Biosciences, Novartis, Pipeline Therapeutics (Contineum), Regeneron, Sanofi-Aventis, Teva Pharmaceuticals, United BioSource, and University of Texas Southwestern, and in consulting for Alexion, Antisense Therapeutics-Percheron, Avotres, Biogen, Clene Nanomedicine, Clinical Trial Solutions, Endra Life Sciences, Cognito Therapeutics, F Hoffman-La Roche, Genentech, Genzyme, Hoya Corporation, Immunic, Immunosis Pty, Klein-Buendel Incorporated, Kyverna Therapeutics, Linical, Merck-Serono, Noema, Neurogenesis, Perception Neurosciences, Protalix Biotherapeutics, Regeneron, Revelstone Consulting, SAB Biotherapeutics, Sapience Therapeutics, Scott & Scott, and Tenmile; has received institutional grants from University of Alabama at Birmingham, AL, USA; and holds non-financial leadership or fiduciary roles in the Birmingham Jewish Federation, Birmingham Jewish Foundation, and Graffman Endowment Committee. HB is an employee of Monash University and board member and managing director of MSBase Foundation. He has received conference travel compensation from Novartis and Merck. His institution received honoraria for talks and lectures from Merck, F. Hoffmann-La Roche Ltd, Novartis. He has received personal compensation for talks from Neuraxpharm. His institution has received compensation for activities in study steering committees, advisory boards, and discussion forums from F. Hoffmann-La Roche Ltd, Novartis, and Merck and research grants from F. Hoffmann-La Roche Ltd., Argenx, Novartis, Merck, UCB Pharma, the Medical Research Future Fund Australia, NHMRC Australia, Trish Foundation, MS Australia, and Monash University. LC is an employee of and shareholder in F. Hoffmann-La Roche Ltd. MR is a contractor for F. Hoffmann-La Roche Ltd. Clinical Trial NCT03523858, ISRCTN15993728 Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Black Country Research Ethics Committee of the UK Health Research Authority and Health and Care Research Wales gave ethical approval for this work regarding the ISRCTN15993728 study. Furthermore, as this manuscript also analyzes data from a decentralized, multinational clinical trial ( NCT03523858 ), equivalent ethical approval was independently obtained from the respective local Institutional Review Boards and Ethics Committees at all participating study sites for that dataset. A complete list of all approving Institutional Review Boards and Ethics Committees for NCT03523858 is provided as the Supplementary Material. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Up-to-date details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents are available on https://go.roche.com/data_sharing. Request for the data underlying this publication requires a detailed, hypothesis-driven, statistical analysis plan that is collaboratively developed by the requestor and company subject matter experts. Such requests should be directed to dbm.datarequest{at}roche.com for consideration. Anonymized records for individual patients across more than one data source external to Roche cannot, and should not, be linked due to a potential increase in risk of patient reidentification. Funder Information Declared Roche (Switzerland), https://ror.org/00by1q217 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted September 07, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Remote ambulation monitoring enhances composite disability measurement in MS to deliver reduced trial sample size Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Remote ambulation monitoring enhances composite disability measurement in MS to deliver reduced trial sample size Andrea Festanti , Dimitar Stanev , Cedric Simillion , João Rodrigues , Letizia Leocani , Agne Kazlauskaite , James Overell , Johannes Lorscheider , Gary Cutter , Helmut Butzkueven , Licinio Craveiro , Mike D Rinderknecht medRxiv 2026.09.03.26361524; doi: https://doi.org/10.64898/2026.09.03.26361524 Share This Article: Copy Citation Tools Remote ambulation monitoring enhances composite disability measurement in MS to deliver reduced trial sample size Andrea Festanti , Dimitar Stanev , Cedric Simillion , João Rodrigues , Letizia Leocani , Agne Kazlauskaite , James Overell , Johannes Lorscheider , Gary Cutter , Helmut Butzkueven , Licinio Craveiro , Mike D Rinderknecht medRxiv 2026.09.03.26361524; doi: https://doi.org/10.64898/2026.09.03.26361524 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (616) Allergy and Immunology (897) Anesthesia (328) Cardiovascular Medicine (4781) Dentistry and Oral Medicine (476) Dermatology (411) Emergency Medicine (646) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1617) Epidemiology (15868) Forensic Medicine (32) Gastroenterology (1196) Genetic and Genomic Medicine (7006) Geriatric Medicine (728) Health Economics (1060) Health Informatics (5011) Health Policy (1429) Health Systems and Quality Improvement (1747) Hematology (583) HIV/AIDS (1338) Infectious Diseases (except HIV/AIDS) (16259) Intensive Care and Critical Care Medicine (1164) Medical Education (665) Medical Ethics (151) Nephrology (721) Neurology (7216) Nursing (366) Nutrition (1074) Obstetrics and Gynecology (1234) Occupational and Environmental Health (1002) Oncology (3584) Ophthalmology (1044) Orthopedics (395) Otolaryngology (449) Pain Medicine (466) Palliative Medicine (139) Pathology (704) Pediatrics (1784) Pharmacology and Therapeutics (733) Primary Care Research (759) Psychiatry and Clinical Psychology (5851) Public and Global Health (9719) Radiology and Imaging (2399) Rehabilitation Medicine and Physical Therapy (1438) Respiratory Medicine (1245) Rheumatology (636) Sexual and Reproductive Health (769) Sports Medicine (577) Surgery (772) Toxicology (107) Transplantation (303) Urology (288)
## Related Clinical Research

- [More REM (dream) sleep linked to lower risk of 83 diseases—UK Biobank study](https://medichelpline.com/clinical-feed/medical-news-today-0-more-dream-sleep-linked-to-lower-risk-of-83-diseases-including-diabetes.md)
- [Carbon monoxide exposure may explain lower Parkinson's risk linked to smoking](https://medichelpline.com/clinical-feed/medical-news-today-0-why-smokers-may-have-a-lower-parkinson-s-risk-it-s-not-the-nicotine.md)
- [Processing Speed Drives the Discriminative Value of a Smartphone Go/No-Go Task in Multiple Scleros](https://medichelpline.com/clinical-feed/medrxiv-15-processing-speed-accounts-for-the-discriminative-power-of-a-smartphone-go-no-go.md)
- [Novartis’ neuromuscular drug del-desiran fails Phase 3 HARBOR trial in DM1](https://medichelpline.com/clinical-feed/stat-news-6-stat-neuromuscular-drug-from-novartis-fails-in-key-study-adding-to-pressure-on.md)
- [Childhood Maltreatment, Poor Sleep, and Fear of Relapse in Multiple Sclerosis: A Clinical Summary](https://medichelpline.com/clinical-feed/medrxiv-1-exploring-the-negative-triad-of-childhood-maltreatment-fear-of-relapse-and-low.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.